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Abstract
Background: Magnesium (Mg) deficiency is common among alcoholics. Earlier research suggests
that Mg treatment may help to normalize elevated enzyme activities and some other clinically
relevant parameters among alcoholics but the evidence is weak.
Methods: The effect of Mg was studied in a randomized, parallel group, double-blind trial. The
patients were first treated for alcohol withdrawal symptoms and then received for 8 weeks either
500 mg of Mg divided into two tablets or matching placebo. Measurements were made at the
beginning and in the end of the Mg treatment period. The primary outcome was serum gamma-
glutamyltransferase (S-GGT) activity; secondary outcomes included aspartate-aminotransferase (S-
AST) and alanine-aminotransferase (S-ALT) activity.
Results: The number of randomized patients (completers) was 64 (27) in the treatment and 54
(31) in the control group. In intention-to-treat-analyses and in most analyses of study completers,
there were no significant differences between the Mg-treated and placebo groups in the outcome
variables. When baseline serum Mg level, coffee intake, and the number of unused Mg tablets were
controlled for in a multivariate regression model, after-treatment serum Mg levels were found to
be higher among the Mg-treated group than in the placebo group (t-test 3.334, df = 53, p = 0.002).
After controlling for age, body weight, baseline alcohol intake, subsequent change in alcohol intake
and baseline S-AST, the after-treatment S-AST levels were found to be lower among the Mg-
treated group than in the placebo group (t-test 2.061, df = 49, p = 0.045).
Conclusion: Mg treatment may speed up the S-AST decrease in compliant patients. This might
decrease the risk of death from alcoholic liver disease.
Trial Registration: ClinicalTrials.gov ID NCT00325299
Background
Magnesium (Mg) deficiency is common among alcoholics
[1-3]. Even in cases with normal serum Mg levels marked
intracellular deficiency may be present. Animal studies
have shown that Mg deficiency aggravates the hepatic
damage caused by alcohol [4]. Mg treatment may help to
normalize elevated enzyme activities and some other clin-
ically relevant parameters, presented below, among alco-
holics but the evidence is weak.
A Norwegian study on chronic alcoholics suggested that
Mg treatment over six weeks decreases abnormally high
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gamma-glutamyltransferase (S-GGT), aspartate-ami-
notransferase (S-AST) and alanine-aminotransferase (S-
ALT), and increases handgrip muscle strength [3]. The
above results were, however, significant at the 5% level
only when a 1-sided test was applied. This may be related
to the small sample size, 24 alcoholics in the treatment
and 25 in the control group. In the treatment for alcohol
withdrawal syndrome Mg administration has been ques-
tioned [5], and a randomized study found no effect of
intramuscular Mg injections on withdrawal symptoms
[6]. However, long-term Mg treatment may help to restore
liver function and other impairments after a drinking
bout, but the evidence is not yet strong enough to warrant
clear recommendations for clinical practice.
Mg deficiency may also be a cause of depression [7]. Mg
ions regulate calcium ion flow in neuronal calcium chan-
nels, helping to regulate neuronal nitric oxide production.
In Mg deficiency, neuronal requirements for Mg may not
be met, causing neuronal damage which could manifest
as depression. Rapid recovery from depression has been
seen in some cases after Mg treatment [8]. Depressive
symptoms are common among alcoholics during with-
drawal from alcohol and often disappear during absti-
nence without any specific drug treatment [9,10]. It thus
seems possible that Mg supplementation might also be
useful in diminishing depressive symptoms among alco-
holics after withdrawal. To clarify the clinical importance
of the above, we studied the effect of oral Mg treatment in
alcoholics, after treatment for alcohol withdrawal symp-
toms, in a randomized, parallel group, double-blind trial.
Confounders were included in the analyses, when appro-
priate [11].
Methods
Planned study population and inclusion criteria
Eligible outpatients admitted to Töölö A-Clinic and
Detoxification Unit (Töölön A-klinikka ja katkaisuhoitoa-
sema in Finnish) in Helsinki, Finland, were invited to the
study when they were about to complete their treatment
for alcohol withdrawal symptoms. This unit treats out-
patients with mild-to-moderate alcohol withdrawal
symptoms. Diagnosis was based on drinking history and
clinical examination. Rating scales and structured diag-
nostic interviews were not used. Day care activities
included counseling, rest, recreational activities and med-
ication, usually decreasing doses of benzodiazepines.
Cases with delirium tremens or other alcohol-related psy-
chosis were referred elsewhere for in-patient treatment.
Thus the study group represents those alcohol withdrawal
symptoms patients that can be treated in units providing
conventional routine outpatient care. Research was car-
ried out in compliance with the Helsinki Declaration. Eth-
ical approval for the trial was granted by the Ethics
Committee of the Helsinki and Uudenmaa Hospital Dis-
trict (Dno 80/E7/2002).
Based on earlier research the average decrease of S-GGT
after Mg treatment was assumed to be 66 U/l and the pop-
ulation standard deviation (SD) 130 U/l (mean of Mg and
placebo group SDs in [3]). At confidence level 95% (1-
alfa) and power level 80% (1-beta), the sample size in
both groups was set at 62 patients [12]. Allowing for 30%
drop-out proportion the aim was to recruit two groups of
89 patients each.
Inclusion criteria were: admission to treatment because of
an acute alcohol withdrawal symptoms or having an ele-
vated S-GGT (men >80, women >50), no more Mg treat-
ment within the past two months except ten 250 mg
tablets or less, age 20–64 years, no history of heart rhythm
disturbances, no contraindications against Mg treatment
(e.g. heart failure, renal failure), normal serum creatinine
and volunteering after informed consent. Moreover,
patients had to have a fixed address and a telephone to
facilitate follow-up. Follow-up appointment dates were
agreed upon before the patients left treatment and they
were contacted by telephone at least twice if they failed to
keep the appointment.
Intervention
The patients received orally for 8 weeks either a daily dose
of 500 mg (20 mmol) of Mg tablets divided in two tablets
(250 mg each) or matching placebo tablets. The tablets
contained a mixture of magnesium carbonate, magne-
sium acetate and magnesium hydroxide. This mixture is
the best compromise between a good uptake without any
laxative effects. The magnesium acetate is valuable if
someone has low stomach acid, because it can be
absorbed even in this case. The tablets were dispensed in
blister packs with 30 tablets in each.
Outcome measures
The primary aim was to confirm that Mg treatment
decreases elevated S-GGT among alcoholics. S-GGT was
chosen to be the primary outcome of the trial because it is
widely used in screening for alcohol problems and corre-
lates with alcohol consumption. The secondary aims were
to find out whether Mg treatment decreases the activity of
S-AST and S-ALT, increases muscle strength and decreases
depressive symptoms among these patients.
Statistical analysis
Because both increase and decrease in the total body Mg
are possible, 2-sided tests were considered to be more
appropriate than 1-sided tests. Differences were consid-
ered significant at the level p < 0.05 (2-sided test). Differ-
ences for categorical variables were assessed with the
Fisher's exact test. The independent sample t-test wasPage 2 of 7
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paired t-test for within-subject change. Main analyses
focused on the end of Mg treatment values of the outcome
variables. Both intention-to-treat and study completer
(per protocol) analyses were made. Because the outcome
variables were continuous, we report means, standard
deviations and t-test significance values. Only the most
relevant data findings are shown. Because some of the dis-
tributions seemed to deviate from normality, nonpara-
metric Mann-Whitney test was also applied. However, the
results were similar (data not shown). Because of the
small sample size, randomization may not have guaran-
teed equal distribution of confounders between the study
groups. Hence multivariate linear regression analysis was
also applied to examine the relation of Mg treatment,
adjusted for confounders, and enzyme activities at the end
of the Mg treatment period of eight weeks. Because ami-
notransferases AST and ALT associate with alcohol intake
and obesity, and weight increases by age, these factors
were considered as confounders [11].
To see how the present results would add to the previous
ones, a general variance-based fixed-effects model to a
continuous measure of effect was applied by pooling the
intervention effects with weights proportional to the
inverse of the variance of the effect from the present and
an earlier study [13].
Assignment and blinding
Patients were randomized as individuals. Codes deter-
mining groups were derived from computer-generated
random numbers and applied with the help of sealed
opaque envelopes. Mg and placebo tablets were identical.
Both groups were told of the possibility of mild diarrhoea
as a side-effect. Code was kept secret by one of us (HA)
and broken after the last patient had had his after-treat-
ment examination.
Measurements
Measurements were made at baseline and at the end of the
8 week treatment period. Alcohol intake was reported by
answering standard questions on the habitual frequency
and quantity of beer, cider, premixed drinks, wine and liq-
uor during the past 30 days. When transforming these
data into alcohol intake (g/day), alcohol contents were
taken to be as follows: beer, cider and premixed drinks
3.6, wine 12 and liquor 30 g/l.
The self-administered 21-item Beck Depression Inventory
(BDI) was used to assess the present depressive state of the
respondent [14,15]. Each item included four or five
graded statements and the respondents were asked to
choose one or more options corresponding most closely
with the actual condition at that time. Each item had
numerical values from 1 to 3 indicating the severity of
depressive mood and the total BDI score range was from
0 to 63. Scores 10–16 suggest mild depression, 17–29
moderate and 30 or more severe depression [14,15].
Maximal handgrip strength was measured in the sitting
position with a Martin strain-gauge dynamometer and
mean of three contractions was considered in data analy-
sis. The reliability of this dynamometer has been found to
be good [16]. Values less than 0.9 kp/cm2 for men aged
50–54 years and less than 0.6 kp/cm2 for women aged 45–
54 years indicate less than average grip strength according
to the reference values by the Institute for Occupational
Health in Finland.
Blood pressure was measured in supine position with an
automatic Omron M5-1 meter. A venous blood specimen
was drawn for determination of S-GGT, S-AST, S-ALT,
serum Mg and serum creatinine. Serum samples were
transported in room temperature to the accredited labora-
tory (VITA Terveyspalvelut Oy, Helsinki, Finland) where
the samples were analysed within a few days. Levels of S-
GGT, S-AST, S-ALT and serum creatinine were measured
by standard kinetic method based on the recommenda-
tion of European Committee for Clinical Laboratory
Standards (ECCLS). Serum Mg was determined by a
standard colorimetric method (Mg-Co, Boehringer Man-
nheim, Germany).
Results
Participant flow and follow-up
Patient flow is shown in Figure 1. The final number of ran-
domized patients was 64 in the treatment and 54 in the
control group. Despite two or more telephone invitations
to those patients who, in spite of their promise to attend,
many subjects failed to keep their follow-up appoint-
ments. The follow-up examination was completed by 58
patients (49%). There were no differences between com-
pleters and dropouts in gender, education, self-rated
health, systolic blood pressure, S-GGT, ALTor S-AST levels
(Table 1). Completers were older, more often married and
had higher diastolic blood pressure (p < 0.05).
Analysis
In intention-to-treat-analyses, there were no significant
differences between the Mg-treated and placebo groups in
the outcome variables (data not shown). Of the compl-
eters, 27 patients were in the treatment group and 31 in
the control group. Respectively, 502 or 16.6% and 749 or
21.6% of all trial tablets were returned. There were no sig-
nificant differences between the treatment and control
groups in change in S-GGT, ALT, S-AST, blood pressure,
maximal handgrip strength or BDI (Table 2). Combining
the present results and the earlier ones [3] by meta-analy-
sis gave a non-significant difference of 3.7 U/l (mean,Page 3 of 7
(page number not for citation purposes)
Substance Abuse Treatment, Prevention, and Policy 2008, 3:1 http://www.substanceabusepolicy.com/content/3/1/1
Page 4 of 7
(page number not for citation purposes)
Participant flowchartFigure 1
Participant flowchart.
       Assessed for eligibility 
(n=134) 
Excluded (n= 16) 
  Not meeting inclusion criteria 
(n=13) 
  Refused to participate 
(n= 3) 
  Other reasons  
(n= 0) 
Analyzed (n=64 and 27) 
Excluded from analysis (n= 0) 
Lost to follow-up (n=37) 
did not attend the after-treatment 
examination despite having 
promised.  
Discontinued intervention 
    (n=not known) 
Allocated to intervention 
   (n= 64) 
Received allocated intervention 
(n=64) 
Did not receive allocated intervention
(n= 0) 
Lost to follow-up (n= 23) 
did not attend the after-treatment 
examination despite having 
promised.  
Discontinued intervention 
    (n= not known) 
    
Allocated to intervention 
(n= 54) 
Received allocated intervention 
(n= 54) 
Did not receive allocated intervention
(n= 0)  
    
Analyzed (n=54 and 31) 
Excluded from analysis (n= 0) 
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pared with the placebo group.
When baseline serum Mg level, coffee consumption and
the number of unused Mg tablets were controlled for in a
linear regression model, after-treatment serum Mg levels
were found to be higher among the Mg-treated group than
in the placebo group (t-test 3.334, df = 53, p = 0.002).
After controlling for age, body weight, baseline alcohol
intake, subsequent change in alcohol intake and baseline
S-AST, the after-treatment S-AST levels were found to be
lower among the Mg-treated group than in the placebo
group (Table 3). The mean S-AST level (SD) was 30.7
(28.9) in the Mg treatment group and 37.6 (30.1) in the
placebo group.
Discussion
We aimed to confirm earlier findings showing that Mg
treatment decreases S-GGT and S-AST, and increases mus-
cle strength in alcoholics. As to most outcomes, confirma-
tion failed, although there were in the present study more
patients and higher Mg dose (500 mg vs. 375 mg) than in
the earlier study [3]. However, since alcohol intake level,
its change, baseline enzyme levels, age and body weight
may influence after-treatment enzyme activity, randomi-
zation may not guarantee balanced groups in a small
study. After controlling for the possible confounders, the
after-treatment S-AST levels were found to be lower in the
Mg-treated group than in the respective placebo group
among the study completers. AST has earlier found to pre-
dict all-cause and liver disease mortality in an eight-year
follow-up study [11]. Thus, we found that Mg treatment
may speed up the S-AST decrease in compliant patients.
This might decrease the risk of death from alcoholic liver
disease.
That not more than 16.6% of all Mg tablets were returned
unused in the Mg treatment group suggests reasonably
good compliance and that possible side-effects of Mg did
not interfere with the treatment. After controlling for
unused Mg tablets and other factors that might have had
an effect on the Mg levels a significant association
between Mg treatment and serum Mg levels was found.
Table 2: Mean change and significance (p) of the difference in study parameters eight weeks after treatment for alcohol withdrawal 
symptoms among 27 patients on magnesium 500 mg per day and 31 patients on matching placebo
Parameter Magnesium Placebo t-test statistic df p value
Systolic blood pressure, mmHg 6.1 ± 18.3 2.1 ± 19.4 0.804 57 0.425
Diastolic blood pressure, mmHg 1.2 ± 9.8 -3.9 ± 10.6 1.922 57 0.058
Grip strength, right hand, kp/cm2 0.03 ± 0.09 0.0 ± 0.11 0.085 57 0.933
Grip strength, left hand, kp/cm2 0.03 ± 0.10 0.05 ± 1.27 1.319 57 0.192
Serum magnesium, mmol/l 0.06 ± 0.12 0.01 ± 0.08 1.801 56 0.077
Serum gammaglutamyl-transferase, U/l -55.4 ± 105 -128.1 ± 49 0.752 56 0.455
Serum aspartateamino-transferase, U/l -22.0 ± 43.8 -34.2 ± 79 0.714 56 0.478
Serum alanineamino-transferase, U/l -12.0 ± 41.0 -24.4 ± 53 0.986 56 0.329
Beck Depression Inventory score -9.1 ± 6.5 -12.2 ± 11 1.236 54 0.222
Table 1: Baseline parameter values among completers and dropouts – Percentages or mean values (± standard deviation) and 
significance (p) of the difference
Parameter (Number of cases) Completers (58) Dropouts (60) t-test df p value
Males, % 63.8 73.3 0.3221
Single, % 20.7 41.7 0.0121
Education < 10 years, % 25.9 30.0 0.6841
Average or poor self-rated health, % 65.5 61.7 0.7051
Age, years 48.7 ± 9.8 41.8 ± 10.3 3.714 116 <0.001
Alcohol intake, g/day 91 ± 93 141 ± 144 2.225 115 0.028
Beck Depression Inventory score 21.1 ± 8.0 20.5 ± 9.3 0.356 113 0.723
Systolic blood pressure, mmHg 139 ± 21.2 134 ± 17.1 1.456 116 0.148
Diastolic blood pressure, mmHg 93 ± 10.3 87 ± 12.3 2.896 116 0.005
Grip strength, right hand, kp/cm2 0.84 ± 0.25 0.87 ± 0.28 0.767 110 0.445
Grip strength, left hand, kp/cm2 0.82 ± 0.27 0.86 ± 0.31 0.782 115 0.436
Serum gamma-glutamyltransferase U/l 158 ± 371 120 ± 169 0.707 116 0.481
Serum aspartate-aminotransferase, U/l 62.9 ± 63 60.9 ± 41 0.205 116 0.838
Serum alanine-aminotransferase, U/l 55.0 ± 49 66.8 ± 59 1.176 116 0.242
1Fisher's exact testPage 5 of 7
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small number of participants. Due to practical difficulties,
low rate of volunteering and unexpected move of the
treatment unit to a new location, the recruiting of patients
had to be closed prematurely. Another problem was the
large number of dropouts. Despite promises to the con-
trary, given during two or more phone calls, the dropouts
did not attend the follow-up examination. Both these
problems decreased the statistical power of the study to
detect significant differences.
Assessment of depression was based on the BDI. This scale
correlates closely with the more accurate Hamilton Rating
Scale for Depression; coefficients have ranged from 0.61
to 0.87 across a variety of clinical populations [15]. How-
ever, since BDI is mainly used as a screening instrument
and does not cover all aspects of depression, the present
results should be verified by further research.
It is possible that some positive effects of the Mg may have
been negated by high alcohol intake before the beginning
of the study or by a relapse to alcohol consumption
among some patients over the Mg treatment period. We
aimed to take this possibility into account by controlling
for the baseline alcohol intake, subsequent change in
alcohol intake in multivariate analyses.
The lack of significant findings between Mg treatment and
most outcomes suggest that either there is no effect or that
the effect is so weak that a larger number of cases are
needed to show the effect. As to S-GGT, the difference
between the present and the earlier study results may be
partly explained by the large inter-individual variation of
the S-GGT response to ethanol that has been observed in
a long follow-up of abstinent and not abstinent alcoholics
[17].
Conclusion
Mg treatment may speed up the S-AST decrease in compli-
ant patients. This might decrease the risk of death from
alcoholic liver disease.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
KP had the idea. KP and HA planned and designed the
study, organized and supervised the data collection and
finalized the manuscript together. KP analysed data and
wrote the first draft.
Acknowledgements
We thank Sirpa Päivinen, R.N. for patient data collection, the Töölö A-
Clinic and Detoxification Unit (Finland) for recruiting the patients and pro-
viding facitilites, Pharma Nord (Denmark) for providing the trial drugs and 
corresponding placebos, and the Finnish Foundation for Alcohol Studies for 
financial support.
References
1. Mussalo-Rauhamaa H, Poikolainen K, Kärkkäinen P, Lehto J:
Decreased serum selenium and magnesium levels in drunk-
enness arrestees.  Drug Alcohol Depend 1987, 20:95-103.
2. Shane SR, Flink EB: Magnesium deficiency in alcohol addiction
and withdrawal.  Magnes Trace Elem 1991, 10(2-4):263-268.
3. Gullestad L, Dolva LØ, Søyland E, Manger AT, Falch D: Oral mag-
nesium supplementation improves metabolic variables and
muscle strength in alcoholics.  Alcohol Clin Exp Res 1992,
16:986-90.
4. Rayssiquier Y, Chevalier F, Bonnet M, Kopp J, Durlach J: Influence of
magnesium deficiency on liver collagen after carbon tetra-
chloride or ethanol administration to rats.  J Nutr 1985,
115:1656-1662.
5. Erstad BL, Cotugno CL: Management of alcohol withdrawal.  Am
J Health Syst Pharm 1995, 52:697-709.
6. Wilson A, Vulcano B: A double-blind, placebo-controlled trial
of magnesium sulfate in the ethanol withdrawal syndrome.
Alcohol Clin Exp Res 1984, 8:542-545.
7. Rasmussen HH, Mortensen PB, Jensen IW: Depression and mag-
nesium deficiency.  Int J Psychiatr Med 1989, 19:57-63.
8. Eby GA, Eby KL: Rapid recovery from major depression using
magnesium treatment.  Med Hypotheses 2006, 67:362-70.
9. Dorus W, Kennedy J, Gibbons RD, Ravi SD: Symptoms and diag-
nosis of depression in alcoholics.  Alcohol Clin Exp Res 1987,
11:150-154.
10. Nakamura MM, Overall JE, Hollister LE, Radcliffe E: Factors affect-
ing outcome of depressive symptoms in alcoholics.  Alcohol Clin
Exp Res 1983, 7:188-193.
11. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I: Normal serum
aminotransferase concentration and risk of mortality from
liver diseases: prospective cohort study.  BMJ 2004, 328:983-9.
12. Armitage P, Berry G: Statistical methods in medical research Oxford,
Blackwell Scientific Publications, Oxford; 1987. 
13. Petitti DB: Meta-analysis, decision analysis and cost-effectiveness analysis:
methods for quantitative analysis in medicine Volume 24. Monographs in
Table 3: The effect of magnesium treatment on serum aspartate-aminotransferase (S-AST), controlling for potential confounders: 
multiple linear regression analysis
Independent variable Regression coefficient Standard error t-test statistic df = 49 p
Study group, Mg vs. placebo -13.640 6.619 2.061 0.045
baseline alcohol intake 0.100 0.102 0.981 0.331
change in alcohol intake 0.120 0.106 1.130 0.264
baseline S-AST 0.052 0.051 1.020 0.313
age -0.299 0.342 -0.874 0.386
weight, kg -0.059 0.210 -0.281 0.780
Constant 40.495 22.116 1.831 0.073Page 6 of 7
(page number not for citation purposes)
Substance Abuse Treatment, Prevention, and Policy 2008, 3:1 http://www.substanceabusepolicy.com/content/3/1/1Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
epidemiology and biostatistics. New York, Oxford University Press;
1994. 
14. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J: An inventory for
measuring depression.  Arch Gen Psychiatry 1961, 4:561-571.
15. Beck A, Steer R, Garbin M: Psychometric properties of the Beck
Depression Inventory: Twenty-five years of evaluation.  Clin
Psychol Rev 1988, 8:77-100.
16. Solgaard S, Kristiansen B, Jensen JS: Evaluation of instruments for
measuring grip strength.  Acta Orthop Scand 1984, 55:569-572.
17. Berglund M, Ojehagen A: Gamma-GT related to drinking pat-
tern in alcoholism.  Acta Pharmacol Toxicol 1983, 53(Suppl II):.
Abstract #3Page 7 of 7
(page number not for citation purposes)
